Epilepsy is a neurological disorder that is characterised by recurrent seizures and affects about 50 million people worldwide. While pharmaceuticals have historically been the primary treatment approach, the landscape of epilepsy management is evolving with the emergence of promising technologies such as neuromodulation devices. GlobalData’s latest models forecast consistent growth for these devices in the near future.
Epilepsy is a seizure disorder, which stems from abnormal electrical discharges in the brain, manifesting in various forms from loss of awareness to full-body seizures. This disorder, with its diverse causes and severities, presents a formidable challenge to healthcare professionals and patients alike. While some epilepsies have known genetic factors, others remain enigmatic in origin.
Go deeper with GlobalData
Despite its prevalence, epilepsy treatment options have historically been limited. However, neuromodulation devices such as deep brain stimulators (DBS) and vagus nerve stimulators (VNS), offer innovative approaches to seizure management. A DBS is a device that comprises a brain-oriented pacemaker (an implantable pulse generator) that sends electrical stimulation through surgically implanted electrodes to specific targets in the brain. A VNS is a device that comprises an electrical pacemaker that sends electrical stimulation through surgically implanted electrodes to target the vagus nerve. Both technologies modulate neural activity to potentially reduce seizure frequency and severity.
Neuromodulation devices are often used to treat severe, but not life-threatening, conditions. The neuromodulation device market was negatively impacted by the Covid-19 pandemic, as procedures that were deemed to be not life-threatening were deprioritised or deferred. However, GlobalData predicts consistent growth for the neuromodulation market in the near future.
GlobalData forecasts positive mid-single-digit growth for the neuromodulation devices market in terms of market share, with segments such as DBS and VNS seeing compound annual growth rates of 6.53% and 5.92%, respectively, between 2023 and 2033.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
